ClinicalTrials.gg
CompletedNCT01734447Updated Feb 28, 2017

Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation

A Phase 4 interventional study of somatropin and somatropin in Foetal Growth Problem and Small for Gestational Age, sponsored by Novo Nordisk A/S. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2017-02-28.

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 12 years 6 months after the study started (first participant enrolled Apr 2000, registered Nov 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
57
Allocation
Randomized
Sex
All
01

Study summary

This trial is conducted in Europe. The aim of this trial is to assess the safety of long-term growth hormone treatment in growth-retarded children with intrauterine growth retardation (IUGR) enrolled in trial GHRETARD/F/1/F.

02

Conditions studied

  • Foetal Growth Problem
  • Small for Gestational Age
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients born with IUGR enrolled in trial GHRETARD/F/1/F
  • Bone age below 14 years in boys and 12 years in girls

Exclusion criteria

Exclusion Criteria:

  • Bone age above 14 years in boys and 12 years in girls
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    1.2, continuous treatment

    Drug: somatropin

  • Experimental
    1.2, non-continuous treatment

    Drug: somatropin

  • Experimental
    2.4, non-continuous treatment

    Drug: somatropin

Interventions

  • 1.2 IU/kg/week, one injection per day, in six days out of seven days, for 12 months

  • 1.2 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)

  • 2.4 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)

06

What researchers measure

Primary outcomes

  1. Glucose tolerance as assessed by hyperglycaemia induced by oral ingestion

Secondary outcomes

  1. Bone Age determined according to Greulich and Pyle method and measured on the left hand X-ray

  2. Pubertal development, assessed according to Tanner method

  3. Height velocity

  4. Final height

  5. Number of Adverse Events

07

Study locations

1 site
  • Novo Nordisk Investigational Site
    Paris, France
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2000 to primary completion in Apr 2003, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2012
First posted
Nov 27, 2012
StartActual
Apr 30, 2000
Primary completionActual
Apr 30, 2003
CompletionActual
Apr 30, 2003
Last update
Feb 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01734447
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 27, 2012
Start date
Apr 30, 2000
Primary completion
Apr 30, 2003
Completion
Apr 30, 2003
Last update
Feb 28, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion